Literature DB >> 21268066

SUMOylation of DLX3 by SUMO1 promotes its transcriptional activity.

Olivier Duverger1, Susie X Chen, Delia Lee, Tianwei Li, P Boon Chock, Maria I Morasso.   

Abstract

Small ubiquitin-like modifiers (SUMO) are post-translational modifiers that regulate target protein activity in diverse ways. The most common group of SUMO substrates is transcription factors, whose transcriptional activity can be altered positively or negatively as a result of SUMOylation. DLX3 is a homeodomain transcription factor involved in placental development, in the differentiation of structures involving epithelial-mesenchymal interactions, such as hair, teeth and nails, and in bone mineralization. We identified two potential SUMOylation sites in the N-terminal domain of DLX3 at positions K83 and K112. Among the six members of the Distal-less family, DLX3 is the only member containing these sites, which are highly conserved among vertebrates. Co-expression experiments demonstrated that DLX3 can be SUMOylated by SUMO1. Site-directed mutagenesis of lysines 83 and 112 to arginines (K83R and K112R) demonstrated that only K112 is involved in SUMOylation. Immunocytochemical analysis determined that SUMOylation does not affect DLX3 translocation to the nucleus and favors perinuclear localization. Moreover, using electrophoresis mobility shift assay (EMSA), we found that DLX3 is still able to bind DNA when SUMOylated. Using luciferase reporter assays, we showed that DLX3(K112R) exhibits a significantly lower transcriptional activity compared to DLX3(WT), suggesting that SUMOylation has a positive effect on DLX3 activity. We identified a new level of regulation in the activity of DLX3 that may play a crucial role in the regulation of hair, teeth, and bone development.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21268066      PMCID: PMC3180851          DOI: 10.1002/jcb.22891

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  34 in total

1.  Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.

Authors:  M Gostissa; A Hengstermann; V Fogal; P Sandy; S E Schwarz; M Scheffner; G Del Sal
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

Review 2.  SUMO: of branched proteins and nuclear bodies.

Authors:  J S Seeler; A Dejean
Journal:  Oncogene       Date:  2001-10-29       Impact factor: 9.867

Review 3.  Intracellular targeting of proteins by sumoylation.

Authors:  V G Wilson; D Rangasamy
Journal:  Exp Cell Res       Date:  2001-11-15       Impact factor: 3.905

4.  Sumo-1 modification regulates the DNA binding activity of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated transcription factor.

Authors:  M L Goodson; Y Hong; R Rogers; M J Matunis; O K Park-Sarge; K D Sarge
Journal:  J Biol Chem       Date:  2001-02-15       Impact factor: 5.157

Review 5.  SUMO and transcriptional repression: dynamic interactions between the MAP kinase and SUMO pathways.

Authors:  Shen-Hsi Yang; Ellis Jaffray; Biruntha Senthinathan; Ron T Hay; Andrew D Sharrocks
Journal:  Cell Cycle       Date:  2003 Nov-Dec       Impact factor: 4.534

6.  Conjugation of Smt3 to dorsal may potentiate the Drosophila immune response.

Authors:  Vinay Bhaskar; Matthew Smith; Albert J Courey
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

Review 7.  Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport.

Authors:  Andrea Pichler; Frauke Melchior
Journal:  Traffic       Date:  2002-06       Impact factor: 6.215

8.  Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1).

Authors:  H Poukka; U Karvonen; O A Janne; J J Palvimo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

9.  Molecular basis for SUMOylation-dependent regulation of DNA binding activity of heat shock factor 2.

Authors:  Yukihiro Tateishi; Mariko Ariyoshi; Ryuji Igarashi; Hideyuki Hara; Kenji Mizuguchi; Azusa Seto; Akira Nakai; Tetsuro Kokubo; Hidehito Tochio; Masahiro Shirakawa
Journal:  J Biol Chem       Date:  2008-11-18       Impact factor: 5.157

10.  The Dlx3 protein harbors basic residues required for nuclear localization, transcriptional activity and binding to Msx1.

Authors:  J T Bryan; M I Morasso
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

View more
  6 in total

Review 1.  Roles of FoxM1 in cell regulation and breast cancer targeting therapy.

Authors:  Xin Song; Samuel Selorm Fiati Kenston; Jinshun Zhao; Danting Yang; Yuanliang Gu
Journal:  Med Oncol       Date:  2017-02-08       Impact factor: 3.064

2.  Neural crest deletion of Dlx3 leads to major dentin defects through down-regulation of Dspp.

Authors:  Olivier Duverger; Angela Zah; Juliane Isaac; Hong-Wei Sun; Anne K Bartels; Jane B Lian; Ariane Berdal; Joonsung Hwang; Maria I Morasso
Journal:  J Biol Chem       Date:  2012-02-20       Impact factor: 5.157

3.  The miR-4739/DLX3 Axis Modulates Bone Marrow-Derived Mesenchymal Stem Cell (BMSC) Osteogenesis Affecting Osteoporosis Progression.

Authors:  Ding Li; Qi Yuan; Liang Xiong; Aoyu Li; Yu Xia
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-02       Impact factor: 5.555

4.  Loss of SUMOylation on ATF3 inhibits proliferation of prostate cancer cells by modulating CCND1/2 activity.

Authors:  Chiung-Min Wang; Wei-Hsiung Yang
Journal:  Int J Mol Sci       Date:  2013-04-16       Impact factor: 5.923

5.  Acidic residue Glu199 increases SUMOylation level of nuclear hormone receptor NR5A1.

Authors:  Chiung-Min Wang; Runhua Liu; Lizhong Wang; Wei-Hsiung Yang
Journal:  Int J Mol Sci       Date:  2013-11-13       Impact factor: 5.923

6.  SUMOylation of FOXM1B alters its transcriptional activity on regulation of MiR-200 family and JNK1 in MCF7 human breast cancer cells.

Authors:  Chiung-Min Wang; Runhua Liu; Lizhong Wang; Leticia Nascimento; Victoria C Brennan; Wei-Hsiung Yang
Journal:  Int J Mol Sci       Date:  2014-06-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.